<div id="readability-page-1"><p>Emerald Mutual Fund Advisers Trust trimmed its holdings in shares of  Omada Health, Inc. (NASDAQ:OMDA - Free Report) by 61.6% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor  owned 61,925 shares of the company's stock after selling 99,302 shares during the period. Emerald Mutual Fund Advisers Trust owned about 0.11% of Omada Health worth $1,369,000 as of its most recent filing with the Securities and Exchange Commission (SEC).</p><p>Other institutional investors have also added to or reduced their stakes in the company. Raymond James Financial Inc. purchased a new stake in shares of  Omada Health in the 2nd quarter worth approximately $32,000.  Rakuten Investment Management Inc. bought a new position in  Omada Health in the third quarter worth approximately $49,000.  Ilex Capital Partners UK LLP purchased a new stake in  Omada Health during the second quarter worth $201,000.  Wilmington Savings Fund Society FSB bought a new stake in  Omada Health during the 3rd quarter valued at $287,000.  Finally, Sandia Investment Management LP bought a new stake in  Omada Health during the 2nd quarter valued at $366,000. </p><h2>Analysts Set New Price Targets</h2><p>Several research analysts have recently commented on the company. Barclays reduced their price target on Omada Health from $29.00 to $22.00 and set an &#34;overweight&#34; rating for the company in a research report on Monday, January 5th. The Goldman Sachs Group  reiterated a &#34;buy&#34; rating and issued a $26.00 target price on shares of Omada Health in a report on Friday, January 16th. Needham &amp; Company LLC  restated a &#34;buy&#34; rating and issued a $28.00 price target on shares of Omada Health in a report on Thursday. Wells Fargo &amp; Company began coverage on shares of Omada Health in a research report on Thursday, January 8th. They issued an &#34;equal weight&#34; rating and a $17.00 price objective on the stock. Finally, BMO Capital Markets began coverage on shares of Omada Health in a research note on Thursday, November 13th. They set an &#34;outperform&#34; rating and a $27.00 price objective for the company. Eight investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one  has assigned  a Sell rating to the company's stock. According to data from MarketBeat.com, Omada Health presently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $25.10.</p><p><b>View Our Latest Research Report on Omada Health</b></p><h2>Omada Health Stock Performance</h2><p>Omada Health stock opened at $16.52 on Friday. The stock has a market cap of $956.67 million and a PE ratio of -66.08. The stock has a 50-day moving average of $16.38 and a two-hundred day moving average of $19.88. Omada Health, Inc. has a one year low of $14.14 and a one year high of $28.40. </p><h2>Insider Activity</h2><p>In other Omada Health news, President Wei-Li Shao sold 5,618 shares of the business's stock in a transaction that occurred on Monday, December 29th. The shares were sold at an average price of $16.13, for a total transaction of $90,618.34. Following the sale, the president owned 69,079 shares of the company's stock, valued at approximately $1,114,244.27. The trade was a 7.52% decrease in their position. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available at this link. Also, CEO Sean P. Duffy sold 230,479 shares of the company's stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $15.60, for a total transaction of $3,595,472.40. Following the transaction, the chief executive officer owned 126,644 shares in the company, valued at $1,975,646.40. The trade was a 64.54% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 276,893 shares of company stock worth $4,336,787. </p><h2>Omada Health Company Profile</h2> (Free Report)<p>Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company's platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.  </p><p>In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Omada Health</li><li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li><li>The $100 Trillion AI Story No One Is Telling You</li><li>Buy This Stock at 9:30 AM on MONDAY!</li><li>A U.S. “birthright” claim worth trillions - activated quietly</li><li>Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T01EQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T01EQQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Omada Health Right Now?</h2><p>Before you consider Omada Health, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Omada Health wasn't on the list.</p><p>While Omada Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

OMDA

<p>Emerald Mutual Fund Advisers Trust reduced its stake in Omada Health, Inc. (NASDAQ:OMDA) by 61.6% in Q3, selling 99,302 shares and retaining 61,925 shares valued at approximately $1.37 million. Other institutional investors have also adjusted their positions. Analysts have set new price targets for Omada Health, with Barclays lowering it to $22.00, while Goldman Sachs maintains a $26.00 target. The stock opened at $16.52, with a market cap of $956.67 million. Insider sales included significant transactions by President Wei-Li Shao and CEO Sean P. Duffy.</p>

Market Beat

iShares US Healthcare Providers

Emerald Mutual Fund Advisers Trust Sells 99,302 Shares of Omada Health, Inc. $OMDA